Collaboration Proposal - COVID-19

03. Apr 2020 | 2 min read

Collaboration Proposal - COVID-19

We at Gentian AS believe it is the duty of all companies in the health industry to help combat the ongoing pandemic of COVID-19/Corona virus. High mortality and long hospitalisation are the consequences of the severe cases with COVID-19 pneumonia. Hence, it is important to identify biomarkers that early could aid in rapid and effective identification of the severely affected patients. In the Gentian test portfolio, the two biomarkers, cystatin C and GCAL® calprotectin, could be useful for the early detection of the severely affected COVID-19 patients. To do our part we are reaching out to research/hospital institutions who want to run a trial to assess whether these biomarkers can make a contribution in the detection of severe COVID-19 cases.

Calprotectin (GCAL®*)as been shown as a promising biomarker in differentiation between bacterial and viral infections [1, 2] and as a useful biomarker for prediction of severe events, including mortality in septic patients [3]. In COVID-19 patients, an early biomarker of neutrophil activation such as calprotectin [4, 5] could be used to early identify patients with bacterial coinfections and patients at risk to develop severe events.

Also, cystatin C providing an accurate estimate of the glomerular filtration function can further help to identify the serious cases amongst patients infected with COVID-19 since renal failure is a frequent complication of acute respiratory distress syndrome as indicated by Dr. Hendrickson et al [unpublished results] and also revealed in COVID-19 patients as indicated by Dr. Xiang and Dr. Wen [unpublished results].

We believe that performing cystatin C and GCAL® calprotectin tests in parallel on the COVID-19 patients could provide additional information for the treating health care professional and we encourage interested researchers to reach out to us at research@gentian.com. We will simultaneously use our network to actively look for study partners, so that this research can be started as soon as possible.

References:

  1. Havelka et al., Sci Rep. 2020 Mar 6;10(1):4208
  2. Bartáková et al., Diagn Microbiol Infect Dis. 2019 Mar;93(3):219-226
  3. Larsson et al. Scand J Clin Lab Invest. 2020 Feb - Apr;80(2):156-161
  4. Jonsson et al., Crit Care Resusc. 2017 Sep;19(3):205-213
  5. Lipcsey et al., Innate Immun. 2019 Aug;25(6):369-373

*In US, for research use only

You may also read


Gentian Newsletter Q3-2020 #DiagnosticEfficiency

Oct 14, 2020

Gentian Newsletter Q3-2020 #DiagnosticEfficiency

We are looking forward to sharing news and exciting things that happened in the last few months. We have for..

Webinar: Frequently asked questions about cystatin C

Oct 06, 2020

Webinar: Frequently asked questions about cystatin C

#FAQ: Cystatin C In the third webinar of the cystatin C webinar series, Shanyil Wickramasinghe, Gentian’s US..

News about Shrunken Pore Syndrome (SPS) and Cystatin C

Sep 28, 2020

News about Shrunken Pore Syndrome (SPS) and Cystatin C

We hope you have had the chance to watch the successful AACC webinar The Use of Biomarkers in Chronic Kidney..